<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">DCTN5 Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>DCTN5</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>DCTN5</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=DCTN5" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">6 edges</a></td>
</tr>
</table>
DCTN5 (dynactin subunit 5, historically p25) is a pointed-end component of the [dynactin complex](/proteins/dynactin-complex), the principal processivity and cargo-selection cofactor for cytoplasmic dynein.[@lau2021][@urnavicius2015][@eckley2012] In [neurons](/entities/neurons), dynein-dynactin function is a rate-limiting determinant of retrograde axonal transport, including delivery of signaling endosomes, autophagosomes, and damaged mitochondria from distal neurites back to the soma.[@zhang2011][@millecamps2013][@de2008]
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">DCTN5 Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>DCTN5</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>DCTN5</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=DCTN5" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">6 edges</a></td>
</tr>
</table>
DCTN5 (dynactin subunit 5, historically p25) is a pointed-end component of the [dynactin complex](/proteins/dynactin-complex), the principal processivity and cargo-selection cofactor for cytoplasmic dynein.[@lau2021][@urnavicius2015][@eckley2012] In [neurons](/entities/neurons), dynein-dynactin function is a rate-limiting determinant of retrograde axonal transport, including delivery of signaling endosomes, autophagosomes, and damaged mitochondria from distal neurites back to the soma.[@zhang2011][@millecamps2013][@de2008]
For neurodegeneration workflows, DCTN5 is best interpreted as a transport-system integrity node rather than an isolated high-penetrance monogenic driver. The strongest evidence tier supports dynein-dynactin pathway failure as a convergent mechanism in [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis)))))))))))), [Parkinson's Disease](/diseases/parkinsons-disease), and [Alzheimer's Disease](/diseases/alzheimers-disease), while direct DCTN5-specific human causality remains comparatively sparse.[@kumakozakiewicz2013][@millecamps2013][@de2008]
Structural and biochemical studies place DCTN5 within dynactin's pointed-end subcomplex together with p27 (DCTN6), p62 (DCTN4), and Arp11. This region is not a passive tail element; it contributes to cargo-facing interfaces and controls adaptor-dependent engagement logic.[@lau2021][@eckley2012][@yeh2004] DCTN5 and DCTN6 are predicted to adopt related left-handed beta-helical folds that support heterotypic interactions needed for stable pointed-end organization.[@yeh2004]
The pointed end helps determine whether the dynein-dynactin assembly is merely assembled versus productively cargo-engaged. In mechanistic terms, DCTN5 contributes to:
Work in fungal and mammalian systems shows that p25 ortholog function is required for efficient dynein interaction with early endosomes and for normal long-range cargo movement.[@zhang2011][@qiu2018] While ortholog experiments should not be over-translated, the conserved transport phenotype supports a strong inference that DCTN5 perturbation can weaken dynamic cargo capture in human neurons.
When retrograde transport efficiency declines, three effects become clinically relevant:
These deficits align with known vulnerability patterns in motor and associative networks implicated across ALS, atypical parkinsonism, and tauopathies.[@millecamps2013][@de2008]
DCTN5 should be analyzed as a multiplier of vulnerability rather than a sole trigger. A moderate pointed-end efficiency reduction may be tolerated in young tissue but can become pathogenic when combined with age-related mitochondrial decline, neuroinflammation, and proteostasis stress. This "multi-hit transport failure" framework is increasingly useful for staging disease progression and selecting biomarkers.[@millecamps2013][@de2008]
Axonal transport dysfunction is repeatedly observed across major neurodegenerative syndromes and experimental models, including dynein-dynactin abnormalities in motor-neuron disease tissue and model systems.[@kumakozakiewicz2013][@millecamps2013][@de2008] This evidence justifies transport-pathway targeting as a core mechanistic axis.
Because DCTN5 is an obligate pointed-end subunit with cargo-targeting implications, altered stoichiometry or interaction-surface integrity is expected to reduce effective cargo engagement probability, especially during stress.[@lau2021][@zhang2011][@qiu2018] This inference is robust mechanistically even when direct genotype-phenotype datasets are limited.
Compared with some other dynactin and motor-complex factors, clinical catalogs currently provide limited direct DCTN5-first disease attribution. This is a knowledge gap, not negative evidence. It motivates targeted human studies rather than pathway dismissal.
DCTN5 is unlikely to function as a stand-alone diagnostic marker, but it can strengthen transport-state panels when integrated with broader axonal injury and proteostasis markers. Useful approaches include:
High-yield experiments for near-term translation include:
Current evidence supports pathway-level intervention logic: improve dynein-dynactin-adaptor performance, stabilize cargo engagement, and preserve retrograde flux. DCTN5-specific targeting may emerge later, but today the higher-confidence route is system stabilization rather than single-protein monotherapy.
For [Corticobasal Syndrome (CBS)](/diseases/corticobasal-syndrome) and [Progressive Supranuclear Palsy (PSP)](/diseases/progressive-supranuclear-palsy), transport impairment can amplify 4R-[tau](/proteins/tau)-mediated stress by reducing organelle quality control and synaptic maintenance. DCTN5 should therefore be viewed as a mechanistic sensitivity factor in circuits already burdened by tau-linked cytoskeletal and trafficking disruption, particularly frontostriatal and brainstem projection pathways.[@millecamps2013][@de2008]
This framing does not imply DCTN5 is a primary causal mutation in most CBS/PSP cases; it supports inclusion of dynactin-pointed-end biology in hypothesis generation, panel design, and combination-therapy logic.